Skip to content

Efficacy and evaluation of human serum albumin supplementation for fluid resuscitation in moderate/severe acute pancreatitis patients: a pilot study

Efficacy and evaluation of human serum albumin supplementation for fluid resuscitation in moderate/severe acute pancreatitis patients: a pilot study

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2300068777
Enrollment
Unknown
Registered
2023-02-28
Start date
2023-03-01
Completion date
Unknown
Last updated
2023-05-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute pancreatitis

Interventions

Test group:5% albumin+ lactate Ringer's solution
Control group:lactated Ringer's solution

Sponsors

The First Affiliated Hospital of Nanchang University
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1) In accordance with the diagnostic criteria of acute pancreatitis in 2012 revision of the Atlanta classification 2) = 72 hours from onset to admission 3) The age is 18-75 years old, regardless of gender 4) Stay in ICU and SIRS = 2 points 5) Willing to follow the research procedure and sign the informed consent form

Exclusion criteria

Exclusion criteria: 1) Have serious allergy to human serum albumin and refuse to accept blood products; 2) Meet the inclusion criteria for more than 24 hours; 3) Albumin or other colloids (such as gelatin) have been infused before the onset of the disease; 4) Pregnant or lactating women; 5) Have suffered from serious cardiovascular, respiratory, liver, kidney, blood and immune diseases, which can be defined as: NYHA grade of cardiac function>grade II; active myocardial ischemia; cardiovascular interventions in the past 60 days; cirrhosis; chronic kidney disease with creatinine clearance<40ml/min or chronic obstructive disease requiring home oxygen therapy. 6) Active bleeding and/or hemoglobin level<70g/L; 7) Patients who have severe respiratory failure, systemic circulatory failure, coma or other irreversible dangerous manifestations and are expected to die within 24 hours.

Design outcomes

Primary

MeasureTime frame
Day 3 SIRS mitigation rate;

Secondary

MeasureTime frame
Resuscitation and hemodynamic parameters;All cause mortality within 28 days;Ventilator free and days alive at 28 days;Days free of renal replacement therapy and alive at 28 days;Days free of vasoactive drugs and alive at 28 days;Incidence of bleeding events;Incidence of gastrointestinal perforation and fistula;

Countries

China

Contacts

Public ContactLiang Xia

The First Affiliated Hospital of Nanchang University

xialiang79@163.com13870871395

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026